Lennar Corporation vs Novo Nordisk A/S — how do they compare? Lennar Corporation trades at $87.46 (market cap $21.05B), while Novo Nordisk A/S trades at $45.92 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 9.9× Lennar Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| LEN | NVO | |
|---|---|---|
Market Cap | $21.05B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $63.98 |
52-Week Low | $81.84 | $35.29 |
Enterprise Value | $24.93B | $222.55B |
Dividend Yield | 2.28% | 3.81% |
Trailing returns across standard periods
Latest headlines on both assets
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →